Nanotechnology

The iQ Group Global secures worldwide license for Harvard University’s eRapid technology for at-home diagnostic testing

Retrieved on: 
Tuesday, March 8, 2022
Engineering, Diagnosis, University, WHO, COVID, Wyss Institute for Biologically Inspired Engineering, Histamine, Patient, Biomarker, Harvard University, World, Insulin, Framework, Technology, Immunity, Blood, Vaccination, Immunoglobulin G, FDA, Solution, Therapy, Nanotechnology, Efficiency, Cancer, COVID-19, Allergy, Medicine, IL6, Johns Hopkins University, Glucagon, Biofouling, Wyss Institute, Wyss, OTFT, Saliva, Physician, Prostate-specific antigen, PSA, World Health Organization, GLOBE, Infection, Vaccine, Medical imaging, Pharmaceutical industry

The eRapid technology was developed by Wyss Founding Director Dr. Donald Ingber and Wyss Senior Scientist, Dr. Pawan Jolly.

Key Points: 
  • The eRapid technology was developed by Wyss Founding Director Dr. Donald Ingber and Wyss Senior Scientist, Dr. Pawan Jolly.
  • Since 2020, The iQ Group Global has collaborated with the Wyss Institute to develop rapid point-of-care SARS-CoV-2 antibody tests.
  • Harvard initially, in 2020, granted The iQ Group Global access to the eRapid technology on a non-exclusive basis, for a limited term, in accordance with the Universitys commitment to the COVID-19 Technology Access Framework .
  • The iQ Group Global is a bioscience investment consortium that finds, funds, and develops bioscience discoveries to create life-changing medical innovations.

The Broad Institute Selects Fabric Genomics in Implementation of Clinical Whole Genome Sequencing Offering

Retrieved on: 
Tuesday, March 8, 2022
Technology, Infectious Diseases, Hospitals, Science, Genetics, Clinical Trials, Cardiology, Diabetes, Biotechnology, Health, Other Science, Other Technology, Nanotechnology, Software, Other Health, Pharmaceutical, Oncology, Broad Institute, Patient, Artificial intelligence, Software, Harvard University, Twitter, Doctor of Philosophy, Entrepreneurship, 100,000 Genomes Project, Gene, MIT, LinkedIn, Genomics, The New England Journal of Medicine, Logic, Association, CEO, Medical genetics, Textile, AI, Classification, American College, Genetic testing, Algorithm, Degenerative disease, Medical device, Medical imaging

Fabric Genomics, Inc., today announced that the Broad Institute of MIT and Harvard has selected the company to support the development and implementation of its clinical whole genome sequencing-based offerings.

Key Points: 
  • Fabric Genomics, Inc., today announced that the Broad Institute of MIT and Harvard has selected the company to support the development and implementation of its clinical whole genome sequencing-based offerings.
  • As part of the agreement, Fabric Genomics will provide the AI-based clinical decision support platform used to support the interpretation of clinical whole genomes and generate patient reports.
  • The collaborators will launch the clinical whole genome interpretation service as part of clinical utility studies with a national healthcare system.
  • The clinical analysis services are powered by a world-class team of variant interpretation geneticists that have interpreted over 10,000 clinical cases in 2021 alone.

RAPID Manufacturing Institute Awarded $9.5MM Grant from NIST to Fund Pandemic Response Projects

Retrieved on: 
Monday, March 7, 2022
Southwest Research Institute, Primary energy, University, Research, Industry, GTRI Agricultural Technology Research Program, Government, American Rescue Plan Act of 2021, Knowledge, American Institute of Chemical Engineers, American Institute, LLC, Chemical engineering, Nanotechnology, Manufacturing USA, Efficiency, Medication, COVID-19, Workforce, NIST, Appalachian Mountains, Paper, Partnership, Coronavirus, RAPID, Department, GLOBE, Innovation Center station, Renewable energy, Fine chemical, Technology

New York, NY, March 07, 2022 (GLOBE NEWSWIRE) -- The RAPID Manufacturing Institute an entity of the American Institute of Chemical Engineers (AIChE) and one of the Manufacturing USA Institutes has been awarded $9.5 million by the U.S. Dept.

Key Points: 
  • New York, NY, March 07, 2022 (GLOBE NEWSWIRE) -- The RAPID Manufacturing Institute an entity of the American Institute of Chemical Engineers (AIChE) and one of the Manufacturing USA Institutes has been awarded $9.5 million by the U.S. Dept.
  • of Commerces National Institute of Standards and Technology (NIST) to conduct three projects involving technology scale-up, workforce development, and testbed development for future pandemic response.
  • In addition to RAPIDs projects, the NIST funding will support the projects of seven other manufacturing innovation institutes in the Manufacturing USA network.
  • The projects are being funded under the American Rescue Plan Act of 2021, also known as the COVID-19 Stimulus Package.

Accelerating the speed of light, euNetworks deploys 7 kilometres of Lumenisity® CoreSmart® hollowcore fibre cable in London

Retrieved on: 
Tuesday, March 8, 2022
Data Management, Semiconductor, Technology, Nanotechnology, Telecommunications, Mobile, Wireless, Networks, Dark, Marketing, Dark fibre, View, City, Acosta Sales & Marketing, ORC, London Stock Exchange, University, Data, EuNetworks, Multimedia, Interxion, Communication, Computer data storage, Internet service provider, Wavelength, euNetworks, Lumenisity® Limited, euNetworks, Lumenisity® Limited, EUNETWORKS, LUMENISITY® LIMITED

Lumenisity Limited (Lumenisity) supplied the award-winning CoreSmart cable which is based on NANF hollowcore technology .

Key Points: 
  • Lumenisity Limited (Lumenisity) supplied the award-winning CoreSmart cable which is based on NANF hollowcore technology .
  • View the full release here: https://www.businesswire.com/news/home/20220308005613/en/
    Data travels 50% faster in hollowcore cable, reducing latency by 1/3, and providing a round trip saving of 3s (three microseconds) per kilometre.
  • The route is the longest commercial deployment of hollowcore fibre technology and its use is exclusive to euNetworks and its customers.
  • Its the second deployment for euNetworks following delivery of the first hollowcore based commercial route in April 2021 .

NeoPhotonics Announces Ultra-Narrow Linewidth Laser for Low Earth Orbit Satellite Applications

Retrieved on: 
Monday, March 7, 2022
Telecommunications, Satellite, Networks, Nanotechnology, Internet, Hardware, Technology, Semiconductor, Cloud, Internet, Private Securities Litigation Reform Act, Laser, ISO, Radiation, Industry, FLASH, Silicon photonics, Security (finance), U.S. Securities and Exchange Commission, Radiation Effects, NeoPhotonics Corporation, Memory corruption, RAM, NYSE, NPTN, Communication, CEO, Telecommunication, Nano, Engineering, Electronics, Technology, Memory, ISO 9001:2015, Silicon

NeoPhotonics current Nano-ITLA laser is in high volume production for terrestrial fiber optics applications and is used by many of the leading optical networking companies in their most advanced coherent pluggable modules and high-speed embedded systems.

Key Points: 
  • NeoPhotonics current Nano-ITLA laser is in high volume production for terrestrial fiber optics applications and is used by many of the leading optical networking companies in their most advanced coherent pluggable modules and high-speed embedded systems.
  • Multiple companies are now deploying or developing constellations of low earth orbit satellites to bring high bandwidth communications to areas not currently served by wireless infrastructure.
  • These constellations consist of thousands of satellites which must have high bandwidth connections between them to avoid service drop-outs.
  • For the lasers used in coherent communication, the control electronics are often more vulnerable to these radiation effects than the laser itself.

NeoPhotonics Announces Inclusion of its Transceivers in the OIF 400ZR Interoperability Demonstration at OFC

Retrieved on: 
Monday, March 7, 2022
Telecommunications, Networks, Nanotechnology, Internet, Hardware, Data Management, Technology, Semiconductor, Cloud, Internet, Laser, ISO, Private Securities Litigation Reform Act, Adoption, OFC, Silicon photonics, Security (finance), U.S. Securities and Exchange Commission, CEI, NeoPhotonics Corporation, OIF, NYSE, Common Electrical I/O, CA, NPTN, CEO, Common Management Information Service, Engineering, Technology, ISO 9001:2015, Silicon, Flex, CMIS, OSFP, Mobile phone

OIF will host its largest demonstration of interoperability to date at this years OFC 2022, featuring five key technology areas 400ZR optics; Co-Packaging architectures; Common Electrical I/O (CEI) channels; FlexE (Flex Ethernet) definitions and Common Management Interface Specification (CMIS) implementations.

Key Points: 
  • OIF will host its largest demonstration of interoperability to date at this years OFC 2022, featuring five key technology areas 400ZR optics; Co-Packaging architectures; Common Electrical I/O (CEI) channels; FlexE (Flex Ethernet) definitions and Common Management Interface Specification (CMIS) implementations.
  • The work of OIF and its members is critical in accelerating the adoption of technologies enabling the networks of today and the future.
  • The interoperability demos will be both live and static at OIFs booth, #5101, during OFC 2022, March 8-10 in San Diego, CA.
  • Were very pleased to participate in the OIF interoperability demo at OFC this year, and our successful interoperability with different manufacturers modules, switches, routers and test equipment helps to establish and expand the 400ZR eco-system, said Tim Jenks, Chairman and CEO of NeoPhotonics.

Freedom Photonics and Vanguard Automation Deploy 3D Nano Printed Chip-Scale Interconnect Manufacturing Capability

Retrieved on: 
Monday, March 7, 2022
Semiconductor, Technology, Manufacturing, Nanotechnology, Software, Other Manufacturing, Hardware, Laser, Vanguard, PIC, Solution, CA, CEO, Photonics, Coupon (PWB), Engineering, Technology, Automation, Programmable interrupt controller, PWB, Printed circuit board, Laser construction

Freedom Photonics and Vanguard Automation announce the deployment of Vanguard Automations SONATA and REPRISE 1000 systems at Freedom Photonicss facilities in Santa Barbara, CA.

Key Points: 
  • Freedom Photonics and Vanguard Automation announce the deployment of Vanguard Automations SONATA and REPRISE 1000 systems at Freedom Photonicss facilities in Santa Barbara, CA.
  • In order to execute these processes in an automated manner in manufacturing, Vanguard Automation has developed two systems, the vanguard SONATA and the vanguard REPRISE.
  • We are extremely excited to bring Vanguard Automation technology in-house, said Dr. Milan Mashanovitch, Chief Executive Officer of Freedom Photonics.
  • We are pleased to be working with Freedom Photonics to enable photonic packaging and integration solutions, said Thorsten Mayer, CEO of Vanguard Automation.

Nooma Bio Announces New Leadership Team to Advance Development of Dual-Nanopore Technology for Ultra High-Resolution Genome and Epigenome Mapping

Retrieved on: 
Monday, March 7, 2022
Other Health, Nanotechnology, Other Science, Other Technology, Research, Oncology, Medical Devices, Hospitals, Genetics, Data Management, Science, Technology, Clinical Trials, Managed Care, Medical Supplies, General Health, Biotechnology, Health, Lynx, Singular, Agilent Technologies, Marketing, Bio, Siemens Healthineers, Khosla Ventures, Research, Ciena, California State University, Doctor of Philosophy, DNA, MGI, Growth, Genomics, New product development, Cancer, Senior, Epigenome, CEO, Pacific Biosciences, BS, Technology, General manager, IBM, Health, Invitae, Management, Microscope, Engineering, NOOMA

Before that, he was President and CEO of Lynx Therapeutics, where he was responsible for the development and commercialization of the companys massively parallel short-read sequencing technology.

Key Points: 
  • Before that, he was President and CEO of Lynx Therapeutics, where he was responsible for the development and commercialization of the companys massively parallel short-read sequencing technology.
  • Launched in 2020 with seed financing from Khosla Ventures, Nooma was founded to accelerate the development and commercialization of the patented dual-nanopore technology.
  • Nooma Bio is developing a proprietary dual-nanopore technology that enables scientists to unlock genome-wide structural and epigenetic variations that drive human health.
  • The companys innovative platform produces ultra high-resolution genome and epigenome maps by performing repetitive electronic scans of oligo-tagged DNA molecules in a matter of seconds.

Fierce Medtech Names Tasso as One of Its “Fierce 15” Med Tech Companies of 2021

Retrieved on: 
Monday, March 7, 2022
Nanotechnology, Pharmaceutical, Research, Software, Medical Devices, Hardware, Hospitals, Data Management, Science, Technology, Practice Management, Nursing, Managed Care, Medical Supplies, Publishing, Biotechnology, Health, Communications, Health, Multimedia, Medical laboratory scientist, Entrepreneurship, Doctor of Philosophy, COVID-19, Technology, Creativity, Face, Investment, CEO, Solution, Research, Industry, Pharmaceutical industry, Accounting, Fierce Medtech, Fierce Medtech, FIERCE MEDTECH

Tasso, Inc., a leader in clinical-grade blood collection technology, today announced that it has been named by Fierce Medtech as one of 2021s Fierce 15 med tech companies, designating it as one of the most promising private med tech companies in the industry.

Key Points: 
  • Tasso, Inc., a leader in clinical-grade blood collection technology, today announced that it has been named by Fierce Medtech as one of 2021s Fierce 15 med tech companies, designating it as one of the most promising private med tech companies in the industry.
  • To be recognized as one of the 2021 Fierce 15 Med Tech Companies is a tremendous honor and another strong validation of our team and technology.
  • The Fierce 15 celebrates the spirit of being fierce championing innovation and creativity, even in the face of intense competition.
  • Fierce Medtech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology.

Upcoming Webinar Discusses How Piezo Motion Products Are Disrupting the Motion Industry

Retrieved on: 
Thursday, March 3, 2022
Public expenditure, Failure, Research, OEM, Forward-looking statement, Income, Solution, Government, Projection, Motion, FDA, EEG, Nanotechnology, SEC, Original equipment manufacturer, CEO, Technology, OTCQB, Neurology, Semiconductor, GLOBE, Electric motor, Risk management

Our products are revolutionizing the precision motor market, said Hassan Kotob, chairman and CEO of Brain Scientific.

Key Points: 
  • Our products are revolutionizing the precision motor market, said Hassan Kotob, chairman and CEO of Brain Scientific.
  • Piezo Motion motors are used globally for a variety of applications.
  • The company is committed to the development of innovative technology and motion products that enhance functionality in a multitude of applications.
  • The Piezo Motion product line consists of ultra-efficient compact precision motors that will drive the next generation of medical devices.